Excellent clinical trial data caused Viking Therapeutics stock to shoot higher in 2024. Eli Lilly markets a diabetes and weight-management drug that is growing sales by leaps and bounds.

Here's what investors should know before adding either one to their portfolios. Viking Therapeutics shares rocketed to an all-time high last February after the company announced positive clinical ...

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market.

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In somewhat of a surprise move, Viking Therapeutics just announced a production deal with CordenPharma, a privately held Swiss company. The move supports the commercial launch of a drug just now ...

Viking Therapeutics, Inc. (VKTX) closed at $29.73 in the latest trading session, marking a +0.61% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.91% for the day.

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against other stocks that are skyrocketing today. The stock market ended mixed on Wednesday ...